Want to see INMB full AI Analyst Report?
INMB Stock Chart & Stats
$1.53
-$0.22(-3.95%)
At close: 4:00 PM EST
$1.53
-$0.22(-3.95%)
Day’s Range― - ―
52-Week Range$1.09 - $3.24
Previous CloseN/A
Volume114.20K
Average Volume (3M)956.61K
Market Cap
$47.59M
Enterprise Value$14.71M
Total Cash (Recent Filing)$21.36M
Total Debt (Recent Filing)$1.51M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Aug 05, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.69
Shares Outstanding26,585,258
10 Day Avg. Volume2,249,951
30 Day Avg. Volume956,613
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.76
Price to Sales (P/S)829.46
P/FCF Ratio-1.76
Enterprise Value/Market Cap0.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-136.23
Enterprise Value/Ebitda-0.59
Forecast
1Y Price Target
$8.00Price Target Upside422.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.7
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Alignment For CORDStrom / EbstrocelClear MHRA alignment and PIP feedback materially de-risk the regulatory pathway for Ebstrocel in an ultra-rare indication. This reduces filing uncertainty, informs Phase 3 design and increases the chance of conditional approval in 2026, strengthening long-term commercialization prospects in the UK/EU.
Manufacturing Readiness And Secured Cord SupplyOn-time process-validation runs plus an exclusive supply/license with Anthony Nolan addresses a key CMC bottleneck for cell therapy scale-up. Reliable GMP supply and validated manufacturing reduce execution risk at approval, supporting durable ability to commercialize off-the-shelf CORDStrom products globally.
FDA Fast Track For XPro (pegipanermin)Fast Track designation formally recognizes XPro's potential clinical value and allows intensified FDA engagement and expedited pathways. For a precision‑medicine Alzheimer’s program, this structurally improves the odds of efficient registrational development and could speed time to market if pivotal trials confirm efficacy.
Bears Say
Pre-commercial Profile With No Product RevenueThe company generates no product sales and posts sustained operating losses and negative free cash flow, meaning operations depend on capital markets. Over months this structural lack of operating revenue limits self-funding and increases execution risk if financing conditions worsen or milestones slip.
Limited Cash Runway / Near-term Financing NeedWith disclosed cash runway into Q1 2027, the company likely needs additional capital within ~12 months. This creates persistent dilution and strategic constraints on trial timing and partner negotiations, forcing near-term financing decisions that materially affect long-term resource allocation.
Significant Reduction In R&D SpendA large YoY cut in R&D spending lowers near-term cash burn but may slow development momentum, delay trials or compress data generation windows. Sustained reductions can impair competitive positioning, risk missing planned regulatory milestones, and undermine long-term value creation of pipeline programs.
Inmune Bio News
INMB FAQ
What was Inmune Bio’s price range in the past 12 months?
Inmune Bio lowest stock price was $1.09 and its highest was $3.24 in the past 12 months.
What is Inmune Bio’s market cap?
Inmune Bio’s market cap is $47.59M.
When is Inmune Bio’s upcoming earnings report date?
Inmune Bio’s upcoming earnings report date is Aug 05, 2026 which is in 24 days.
How were Inmune Bio’s earnings last quarter?
Inmune Bio released its earnings results on May 07, 2026. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.245 by $0.045.
Is Inmune Bio overvalued?
According to Wall Street analysts Inmune Bio’s price is currently Undervalued.
Does Inmune Bio pay dividends?
Inmune Bio does not currently pay dividends.
What is Inmune Bio’s EPS estimate?
Inmune Bio’s EPS estimate is -0.19.
How many shares outstanding does Inmune Bio have?
Inmune Bio has 26,585,258 shares outstanding.
What happened to Inmune Bio’s price movement after its last earnings report?
Inmune Bio reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.245. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Inmune Bio?
Currently, no hedge funds are holding shares in INMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inmune Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (422.88% Upside)
$8.00 (422.88% Upside)
Blogger Sentiment
Bullish
INMB Sentiment 70%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.15%
12-Months-Change
Fundamentals
Return on Equity
-170.86%
Trailing 12-Months
Asset Growth
-31.70%
Trailing 12-Months
Company Description
Inmune Bio
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
INMB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful, tangible progress toward a key inflection point: CORDStrom advanced through regulatory planning (PIP approval), manufacturing validation runs began, and a long-term supply agreement was secured — all supportive milestones. XPro imaging work and partnership exploration were also positive. Offsetting these positives are schedule/regulatory timing shifts, a materially limited cash runway (funding through Q1 2027), and a large year-over-year reduction in R&D spend that could indicate slower near-term investment. Overall the call shows constructive execution on regulatory and manufacturing fronts but meaningful financing and execution risks remain.View all INMB earnings summariesINMB Stock 12 Month Forecast
Average Price Target
$8.00
▲(422.88% Upside)
Technical Analysis
Veru
―
Karyopharm Therapeutics
―
Cue Biopharma
―
Celularity
―
Jupiter Neurosciences, Inc.
―
Ownership Overview
11.28% Insiders
4.91% Mutual Funds
1.70% Other Institutional Investors
78.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---